O

ne of the highest-profile researchers in diabetes has retracted a paper once heralded as a breakthrough, following multiple failed attempts to reproduce its headline-grabbing results.

The retraction ends three years of scrutiny into whether a discovery by Harvard University stem cell scientist Douglas Melton was indeed a major advance in the field of diabetes, with the paper’s authors now conclusively backing away from their earlier findings.

Back in 2013, Melton’s lab reported a promising discovery: A hormone found in the liver seemed to spur the production of insulin-producing cells in mice, lighting the way for a new approach to treating diabetes. The paper, published in the journal Cell, drew attention around the world, as it suggested a means of boosting insulin by using the body’s own machinery and held out the potential to free millions of diabetes patients from regular injections.

advertisement

But the claim soon lost its luster.

In 2014, an independent group of researchers found that the hormone, which Melton’s lab dubbed betatrophin, had no effect on insulin production. Melton’s team then published a follow-up that cast similar doubts on the initial findings. Earlier this year, Melton joined researchers from Baylor College of Medicine and the Harvard-affiliated Joslin Diabetes Center in publishing a strong refutation of the idea that betatrophin can mobilize a spike in insulin production.

In a retraction notice posted this week, Melton and his Harvard co-authors concede that their initial conclusion “is wrong and cannot be supported,” effectively burying the once-promising idea.

Melton, who was on vacation and unavailable for comment Tuesday, told the Retraction Watch blog he chose to pull the paper in hopes of avoiding confusion.

It’s a disappointment, like any retraction, but the gradual teardown of the betatrophin hypothesis illustrates “how scientists can work together when they disagree, and come together to move the field forward,” Melton said.

“The history of science shows it is not a linear path,” he added.

Melton is a pioneer in stem cell research, through which biological blank slates can be transformed into any type of bodily cell. He embraced the idea in the early 1990s after his son was diagnosed with Type 1 diabetes, setting out to turn moldable stem cells into beta cells, the body’s insulin factories, in hopes of crafting a cure for the disease.

That work set him down the path to betatrophin. In Melton’s initial paper, injecting mice with the new-found hormone led to a 17-fold increase in pancreatic beta cells. If the effect could be replicated and transferred to humans, Melton thought, diabetics might one day be able to trade their daily injections of insulin with a dose of betatrophin that could be administered as infrequently as once a year.

But replication never came.

That first test involved just seven mice, and when Melton’s team ran five more experiments on 52 mice, the magnitude of beta cell production fell considerably. Separately, a group of researchers led by Regeneron Pharmaceuticals’ Viktoria Gusarova tried both knocking out and dialing up the production of betatrophin, only to find that neither had a marked effect on beta cells.

To give the hypothesis a final shake, Melton recruited researchers from Baylor and Joslin to run a blinded study. In the end, all three groups came to the same conclusion: Betatrophin offered little hope as a treatment for diabetes.

Correction: A previous version of this story incorrectly described the groups that published a study in 2016 refuting the idea that betatrophin can spur the creation of insulin-producing beta cells. The researchers who worked with Melton on that study were from Baylor College of Medicine and Joslin Diabetes Center.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Behind you all the way, Doug Melton. You have been present in each of my classes showing your wonderful work. As Mary ann Stone says, “God will use you in a powerful way. Keep faith”. Mom of Peter, a T1.

  • Behind you all the way, Doug Melton. You have been in my prayers for the past 5 years. I know God will use you in a mighty way. Keep the faith. Mom of a t1

  • I remember reading about this shortly after my daughter was diagnosed, I believe it was stated that Infinite amounts of Islet cells are able to be created, one of the stumbling blocks preventing Islet Cell Transplantation. Why was this Hailed as ” The Cure is in Reach” if NOT EVEN PROVEN. How much of this ” Never Ending Funding” is being WASTED. Is this Disease just a JOKE. From Grad School through Retirement with NOTHING to show for ALL THIS SO CALLED RESEARCH other than electronic Testers and Delivery Systems. Lets create the Cure, Prove it then announce it to the World, but make sure you can GENERATE the same CASH FLOW as you do TREATING this ROBBING and HORRIBLE DISEASE. If I were a Mouse, I would have been CURED by now.

    • I don’t believe that other finding (the one about islet cells being endlessly produced) is retracted at all. That’s a separate study/discovery. Also, this is how science works. It’s not linear. Finally, I’m quite sure Dr. Melton doesn’t think it’s a joke if both of his kids have it.

  • B.D.Colen thank you for the explanation. But it illustrates my point, even if I had it backwards. The article did not make a distinction between types 1 and 2 or make clear what you have explained, that it was originally geared to type 2. (Also, I didn’t know that type 1 had reached epidemic proportions worldwide.)

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

X